Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 23, 2012 16:00 ET | Source: 21st North Inc.

Urologix Reports Results for Fourth Quarter and Fiscal Year 2012

Fiscal year 2012 revenue increased 35% over the fiscal year 2011 period in line with annual guidance Fourth quarter revenue of $4.5 million up 54% year-over-year and down 5%...
August 07, 2012 13:00 ET | Source: 21st North Inc.

Urologix Announces Closing of Over-Allotment Option

MINNEAPOLIS, Aug. 7, 2012 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced the...
July 18, 2012 14:00 ET | Source: 21st North Inc.

Urologix Regains NASDAQ Compliance With Minimum Shareholders' Equity Requirement

MINNEAPOLIS, July 18, 2012 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, announced today it...
July 05, 2012 11:00 ET | Source: 21st North Inc.

Urologix Announces Closing of Follow-On Offering

MINNEAPOLIS, July 5, 2012 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced the...
June 29, 2012 09:21 ET | Source: 21st North Inc.

Urologix Announces Pricing of Follow-On Offering of 5,200,000 Shares of Common Stock

MINNEAPOLIS, June 29, 2012 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced...
May 14, 2012 16:06 ET | Source: 21st North Inc.

Urologix Announces Three Events at the 107th Annual Meeting of the American Urological Association

Sponsor of Expert Panel Lecture on In-Office BPH Therapies, Moderated by Dr. Claus Roehrborn Presentation of Cooled ThermoTherapy™ (CTT) Clinical Outcomes for Improving Nocturia by Dr....
April 26, 2012 16:00 ET | Source: 21st North Inc.

Urologix Reports 59% Increase in Revenue Year-Over-Year for Fiscal 2012 Third Quarter

$4.7 million in total revenue, up 2% sequentially Positive cash flow in the quarter of $285 thousand Full year 2012 revenue guidance between $17.0 to $17.5 million MINNEAPOLIS, April...
January 24, 2012 16:00 ET | Source: 21st North Inc.

Urologix Reports 48% Increase in Sequential Revenue for Fiscal 2012 Second Quarter

$4.7 million in revenue, 40% quarterly revenue growth year over year Positive cash flow in the quarter of $17 thousand $2 million credit facility established MINNEAPOLIS, Jan. 24, 2012...
January 12, 2012 16:00 ET | Source: 21st North Inc.

Urologix Secures $2 Million Credit Facility

MINNEAPOLIS, Jan. 12, 2012 (GLOBE NEWSWIRE) -- Urologix, Inc. (Nasdaq:ULGX), the market leading medical device company for in-office procedures to treat BPH that provide safe, durable and effective...
January 06, 2012 15:00 ET | Source: 21st North Inc.

Urologix Regains Nasdaq Minimum Bid Price Requirement

MINNEAPOLIS, Jan. 6, 2012 (GLOBE NEWSWIRE) -- Urologix, Inc. (Nasdaq:ULGX) is the market leading medical device company for in-office procedures to treat BPH that provide safe, durable and effective...